ITCI Intra-Cellular: Year-over-year net earnings per share growth for the last 12 months
Intra-Cellular Therapies (ITCI) profitability is based on the demand for drugs used in the therapy of bipolar disorders and schizophrenia. This quarterly EPS chart visualizes profit dynamics, where the 45.50 mark reflects the latest data. The company's growth relies on close cooperation with specialized clinics. Patent protection and the high efficacy of its flagship product allow the issuer to confidently capture the market while avoiding price wars with generics.
Financial and market metric breakdowns for Intra-Cellular Therapies, Inc. (ITCI)
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Intra-Cellular Therapies|ITCI - Long-Term Debt to Equity|Short-Term Debt to Equity Intra-Cellular Therapies Inc.|ITCI - Company Debts|Debt to Book Value Intra-Cellular Therapies, Inc.|ITCI - Company Long-Term Debts|Company Short-Term Debt Intra-Cellular Therapies|Quick Ratio intracellulartherapies.com
- earnings and valuation multiples indicators:
ITCI - Net Profit|Expected Profit Intra-Cellular Therapies|ITCI - Company Value to Net Income|Projected Price to Earnings Intra-Cellular|ITCI - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Intra-Cellular|ITCI - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Intra-Cellular Therapies|ITCI - Earnings per share for the trailing year|Quarterly EPS earnings growth intracellulartherapies.com|ITCI - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Intra-Cellular Therapies
- revenue and sales proceeds data:
Fundamental valuation:Intra-Cellular, ITCI
The strong pricing power of Intra-Cellular Therapies (ITCI) in the schizophrenia drug market transforms stable medical demand into sustainable earnings per share growth. By analyzing the quarterly relative change in EPS, investors assess net income growth rates compared to the same period last year, allowing them to verify the effectiveness of patent commercialization and confirm the fundamental quality of the growing asset.
Competitor analysis
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Bioscience Ltd) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Axsome Therapeutics, Inc. AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals Inc.)|XENE: Year-over-year net earnings per share trend for the last twelve months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals (SUPN)|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Therapeutics)|HRMY: Quarterly EPS earnings growth|BHVN (Biohaven Pharmaceutical) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Amylyx|Quarterly EPS earnings growth Trevi Corp|Quarterly EPS earnings growth PRAX|AVXL (anavex.com) - Year-over-year earnings per one share growth for the last 12 months|CeriBell Inc - Year-over-year net earnings per share growth for the last 12 months|PRTA (Prothena Corporation plc) - Year-over-year net earnings per share trend for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|ANNX (Annexon Biosciences Inc.) - Year-over-year earnings per share growth for the last 12 months|OMER (omeros.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months NGNE|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth Voyager Pharma|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|SCLX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tevogen Bio TVGN|Alpha Cognition Corp (ACOG) - Earnings per share growth in annualized terms for the last twelve months|CGTX: Year-over-year net earnings per share growth for the last 12 months|Inhibikase Therapeutics, Inc. - Year-over-year earnings per share growth rate for the last twelve months|SAVA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ASRT|COYA (coyatherapeutics.com) - Quarterly EPS earnings growth|Vistagen (VTGN) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OVID (Ovid Rx)|Year-over-year net earnings per share change for the last twelve months Acumen Pharmaceuticals, Inc.|Quarterly EPS earnings growth CRVO (CervoMed Corporation)|Year-over-year earnings per share growth rate for the last twelve months ATHE (Alterity Therapeutics Ltd)|Clene Nanomedicine - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year pepgen.com (PEPG)|JUNS: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RLMD|ANVS (Annovis Bio Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Grace Therapeutics, Inc. (GRCE)|Quarterly EPS earnings growth AIFF|Year-over-year earnings per share growth rate for the last twelve months KLTO|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings (RVPH) - Earnings per share growth in annualized terms for the last twelve months|MetaVia Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months NeurAxis Inc NRXS|HSDT (Helius Medical Technologies Inc.) - Year-over-year net earnings per share growth for the last 12 months|Passage Bio Inc. (PASG) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Neuphoria|Year-over-year net earnings per share growth for the last 12 months Minerva Neurosciences, Inc. (NERV)|Year-over-year earnings per share growth for the last twelve months Athira (ATHA)|Addex Therapeutics - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Alzamend Neuro, Inc. ALZN|Cyclerion (CYCN) - Earnings per share growth in annualized terms for the last twelve months|PTIX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Pasithea Therapeutics Corp KTTA|Cortigent, Inc. (CRGT) - Year-over-year earnings per share growth for the last twelve months|Avenue Therapeutics - Year-over-year earnings per one share growth for the last 12 months|BCLI (brainstorm-cell.com) - Quarterly EPS earnings growth|CARA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Chromocell Therapeutics Corp (CHRO)|ELYM (Eliem Therapeutics Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth LBPH (Longboard Pharmaceuticals Inc)|Quarterly EPS earnings growth Marinus Pharma MRNS|nkgenbiotech.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharmaceuticals, Inc.|Sage Therapeutics (SAGE) - Year-over-year earnings per share growth for the last twelve months|SNPX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Trevena, Inc|Vigil Neuroscience (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth cerevel.com (CERE)
